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Objective To compare the impact of 1000 micrograms of self-administered
vaginal misoprostol versus self-administered vaginal placebo at home on pre-
operative cervical ripening in both premenopausal and postmenopausal
women before operative hysteroscopy.
Design Two separate but identical parallel, randomised, double-blind,
placebo-controlled sequential trials, one in premenopausal women and one
in postmenopausal women. The boundaries for the sequential trials were
calculated on the primary outcomes of a difference of cervical dilatation
‡1 mm, with the assumption of a type 1 error of 0.05 and a power of 0.95.
Setting Norwegian university teaching hospital.
Sample Eighty-six women referred to outpatient operative hysteroscopy.
Methods The women were randomised to either 1000 micrograms of
self-administered vaginal misoprostol or self-administered vaginal placebo
the evening before outpatient operative hysteroscopy.
Main outcome measures Preoperative cervical dilatation (primary
outcome), number of women who achieve a preoperative cervical dilatation
‡5 mm, acceptability, complications and adverse effects (secondary
outcomes).
Results In premenopausal women, the mean cervical dilatation was
6.4 mm (SD 2.4) in the misoprostol group and 4.8 mm (SD 2.0) in the
placebo group, the mean difference in cervical dilatation being 1.6 mm
(95% CI 0.5–2.7). Among the premenopausal women receiving misoprostol,
88% achieved a cervical dilatation of ‡5 mm compared with 65% in the
placebo group. Twelve percent of the women who received misoprostol
were difficult to dilate compared with 32% who received placebo. Dilatation
was also quicker in the misoprostol group. Misoprostol had no effect on
cervical ripening in postmenopausal women compared with placebo, and
43% of the women were difficult to dilate. The trials were terminated after
analysis of 21 postmenopausal women and 65 premenopausal women after
reaching a conclusion on the primary outcome with only 28% of the
number of women needed in a fixed sample size trial. Three of 45 women
who received misoprostol experienced severe lower abdominal pain, and
there was an increased occurrence of light preoperative bleeding in the
misoprostol group. Most women did not experience misoprostol-related
adverse effects. The majority (83% of premenopausal and 76% of
postmenopausal women) found self-administered vaginal misoprostol at
home to be acceptable. There were two serious complications in the
premenopausal misoprostol group: uterine perforation with subsequent
peritonitis and heavy postoperative bleeding requiring blood transfusion,
but these were not judged to be misoprostol related. Complications were
otherwise comparatively minor and distributed equally between the two
dosage groups.
Conclusions One thousand micrograms of self-administered vaginal
misoprostol 12 hours prior to operative hysteroscopy has a signiﬁcant cervical
ripening effect compared with placebo in premenopausal but not in
postmenopausal women. Self-administered vaginal misoprostol of 1000
micrograms at home the evening before operative hysteroscopy is safe and
highly acceptable, although a small proportion of women experienced severe
lower abdominal pain. There is a risk of lower abdominal pain and light
preoperative bleeding with this regimen, which is very cheap and easy to use.
Keywords Cervical ripening, misoprostol, premenopausal, postmeno-
pausal, sequential trial.
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www.blackwellpublishing.com/bjog Gynaecological surgeryIntroduction
Over the past 20 years, minimally invasive operative techni-
ques have been introduced for treating intrauterine pathol-
ogy. Operative hysteroscopy or resectoscopy is the most
common method for treating intrauterine pathology, such
as myomas and endometrial polyps. Endometrial resection
is a standard treatment of abnormal uterine bleeding if less
invasive procedures fail.1 The diameters of resectoscopes
(usually Charriere 24 or 26) necessitate dilatation of the cer-
vical canal to 10 or 11 mm prior to insertion of the instru-
ment. The complications encountered during dilatation, such
as cervical tears, creation of false passages, and uterine perfo-
ration, are reported to be mainly related to the difﬁculty of
cervical dilatation in nulliparous and postmenopausal
women.2 An audit of women who have undergone operative
hysteroscopy in our department supports this3 and reports
a 7.8% complication rate related to hysteroscopic resection
of endometrial polyps.
Prevention of cervical injury and uterine perforation dur-
ing termination of pregnancy has been demonstrated by
preoperative cervical ripening4,5 and may be achieved either
mechanically, such as with osmotic dilators,6 or biochemically
with prostaglandins.7 Solid evidence supports the efﬁcacy of
misoprostol for cervical ripening in pregnant women before
ﬁrst-trimester suction curettage abortion.7,8
In contrast, misoprostol for cervical ripening in nonpreg-
nant women to prevent cervical injury during dilatation is not
well established. We found 17 reported randomised con-
trolled trials published in English that evaluated the efﬁcacy
of misoprostol on cervical ripening in nonpregnant women
published before 1 September 2006, after searching medical
literature databases including Pubmed9 and EMBASE Ovid.10
The search terms used included ‘misoprostol’, ‘cervical ripe-
ning/priming’ ‘hysteroscopy’, and ‘operative hysteroscopy’.
References from identiﬁed publications were manually
searched and cross-referenced to identify additional relevant
articles. The studies have shown different cervical response
and outcomes.11–28 Most of the studies have separately, but
not systematically, compared the effect on different groups
of women, such as nulliparous women and postmeno-
pausal women. Eight of the studies included less than 50
women,12,13,16,18,20–22,25 four did not compare the effect of
misoprostol with a placebo,23–25,27 and ten of the trials appear
to be underpowered or lacking a sample size calculation as re-
gards to evaluating primary outcome measures.11–13,16–18,20–22,26
It appears that none of the trials has been designed and
conducted in accordance with the CONSORT statement.28
The dosages used in the studies have varied between 200
and 1000 micrograms of misoprostol given between 2 and
24 hours before hysteroscopy, via oral, sublingual, and vaginal
routes. A review by Crane and Healy29 concludes that in pre-
menopausal women, misoprostol appears to be promising as
a cervical ripening agent prior to hysteroscopy, although
further research is needed to identify the ideal dose, route,
and timing. Further research in postmenopausal women or
those receiving gonadotrophin-releasing hormone (GnRH)
agonists (a group perceived as having an additional risk fac-
tor for complications)2 has been recommended to determine
whether misoprostol is effective in cervical ripening in this
population. Trials that have used higher dosages of misopros-
tol, via the vaginal route, using the longest time interval be-
tween administration of misoprostol and hysteroscopy have
tended to show more favourable outcomes regarding cervical
ripening.
Judging cervical width in millimetres preoperatively with
dilators used in clinical practice is a normal method of assess-
ing the effect of cervical ripening.12–17,19–27 Less commonly,
preoperative ripening is assessed by measuring cumulative
dilatation force using a cervical tonometer.11,13,16 Cervical
resistance to dilatation or complications encountered during
the procedure are also parameters that can indicate effective-
ness of cervical ripening. The aim of our study was to inves-
tigate whether 1000 micrograms of self-administered vaginal
misoprostol 12 hours before operative hysteroscopy results
in effective preoperative cervical ripening compared with
placebo.
Methods
The study protocol was designed according to the recommen-
dations in the CONSORT statement28 and was submitted to
BJOG for review before recruitment of women. The study was
a randomised, controlled, double-blind one-centre study at
a central university gynaecological outpatient department. All
women referred to outpatient operative hysteroscopy at
Ulleva ˚l University Hospital between 1 August 2006 and 20
April 2007 were sent an invitation to be included in the study.
Women are referred to our hospital for operative hystero-
scopy from private practising gynaecologists, GPs or other
hospitals. The common presenting complaints are abnor-
mal/postmenopausal uterine bleeding, endometrial polyps,
submucous myomas, and infertility. The invitation for study
participation was sent together with dates for a preoperative
outpatient consultation. The study invitation included de-
tailed information regarding the study, as well as an informed
consent form. The outpatient consultation took place a few
days prior to the scheduled operation, where the women
received additional information and were given the option
to participate in the study. Women who had a medical indi-
cation for operative hysteroscopy and who had given
informed consent were eligible for study recruitment. Exclu-
sion criteria were as follows: women who were unable to
communicate in Norwegian, women without an indication
for hysteroscopy, women who were medically unﬁt for sur-
gery and women with a known allergy to misoprostol.
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April 2007 (Figure 1). Doctors examining women at the out-
patient consultation (trainees and specialists) were responsi-
ble for recruiting the women. During the 8 months the study
was carried out, 82% of the total number of premenopausal
women and 79% of the total number of postmenopausal
women referred to operative hysteroscopy participated in
the study. The rest declined the offer (11% of the premeno-
pausal and 10% of the postmenopausal women) or were
excluded based on the exclusion criteria (7% of the premen-
opausal and postmenopausal women). Two separate, but
identical, studies were conducted in parallel, based on the
women’s menopausal status. Each participant received either
1000 micrograms of misoprostol or placebo, which they self-
inserted vaginally at least 12 hours before operative hystero-
scopy. The randomisation was performed with permuted
blocks, using the randomisation plan generator, as described
by Dallal.30 The randomisation procedure was third party
concealed randomisation, performed by the hospital pharma-
cist. Placebo misoprostol tablets are difﬁcult to make; there-
fore, gelatine capsules with an identical appearance were
manufactured by the hospital pharmacist. The active miso-
prostol was ground up as a whitish powder inserted into
gelatine capsules (500 microgram misoprostol per capsule),
as was an inactive ingredient, lactosum monohydricum—
which has an identical appearance to ground misoprostol
tablets—and subsequently inserted into gelatine capsules
as placebo. The hospital pharmacist prepared numbered,
opaque, sealed plastic containers labelled ‘Misoprostol
0.5 mg/Placebo, 2 vaginal capsules’. The prepared capsules
were inserted into containers by the hospital pharmacist,
which were sealed with tamper-proof seals. Each container
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5 did not attend outpatient clinic
2 no indication for hysteroscopy 
Figure 1. Flow diagram.
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capsules with 500 microgram misoprostol each, while the
other half contained two placebo capsules. The containers
were then delivered to the outpatient clinic. As the women
were recruited, the doctor at the outpatient consultation
recorded the preoperative variables on a standardised case
report form (on page 1), and the women were given a plastic
container containing the capsules before leaving the hospital.
Hence, those involved in administering the intervention and
the women were blinded to the treatment received. Each
study participant opened a numbered container at home,
containing either misoprostol or lactosum monohydricum
in capsules. The women were instructed to insert the capsules
as deep as possible vaginally after voiding urine at approxi-
mately 9 p.m. the evening before the operation.
On admission to the operating theatre, nurses recorded
symptoms and comments from the women on the case report
form (page 1). The women recorded pain experienced
betweentheinsertionofcapsulesandtheoperationonavisual
analogue scale score, ranging from 0 (no pain) to 10 (unbear-
able pain). Women were asked to rate acceptability of self-
administered capsules on a scale from 1 to 4 (1 = completely
acceptable, 2 = fairly acceptable, 3 = fairly unacceptable, 4 =
completely unacceptable). The women were then given a gen-
eral intravenous anaesthetic (propofol/fentanyl/alfentanyl) by
the attending anaesthesiology nurse, after which the nurses
prepared the women for operation by disinfecting the vulval
and vaginal area with a 0.05% chlorhexidine acetate solution
(Fresenius Kabi, Halden, Norway). Visible vaginal capsule
remains were noted before the area was irrigated. The case
report form with the preoperative variables, recorded symp-
toms and comments from the women on page 1 was then
turned over to page 2, so that this information was not avail-
able to the operating gynaecologist. The operators were then
summoned to the operating theatre. They were thus both
blinded to which treatment the women had received and to
the occurrence of possible adverse effects from the treatment,
as recorded by the nurses.
Six experienced senior gynaecologists (with 5–20 years ex-
perience in operative hysteroscopy) performed the operative
hysteroscopies during the study period. Prior to operation of
the first woman, the project leader individually instructed the
operators in assessing preoperative cervical dilatation in order
to obtain valid and reliable measurements. Before the opera-
tive hysteroscopy, the operator measured the preoperative
degree of cervical dilatation by passing Hegar dilators through
the cervix in ascending order starting with a size of 4 mm. The
size of the largest dilator passed into the inner cervical ostium
without subjective resistance felt by the operator was recorded
as the preoperative degree of dilatation. If there was initial
resistance with Hegar dilator of size 4 mm, then dilators of
size 3 or 2 mm were tried. If there was resistance with Hegar
dilator of size 2 mm, the result was recorded as 0 mm. After
the cervical canal was dilated to a Hegar dilator of size 10 or
11 mm, an Olympus (Olympus, Hamburg, Germany) rigid
resectoscope model A22026A (Charriere 26) equipped with
a Hopkins 12  rigid fibre optic model A22001A was passed
into the uterine cavity. A sodium chloride 9% solution
(Baxter, Norfolk, UK) was infused for uterine irrigation. A
bipolar diathermal current of 280watts (pure cut) suppliedby
a Surgmaster  US-40 (Olympus) diathermia unit was rou-
tinely used for resection of pathological uterine masses (myo-
mas, polyps, uterine septae, etc.) and endometrium. For
haemostasis coagulation, a current of 80 watts was applied.
Adverse events during the operation, such as superﬁcial cer-
vical lacerations, production of false passage of the cervix
during cervical dilatation, and perforation of the uterus were
recorded. The women’s records were reviewed after 14 days
for postoperative complications.
The null hypotheses for the trials were that there is no
clinically signiﬁcant difference in preoperative baseline cervi-
cal dilatation (<1 mm), between women who receive miso-
prostol and those who receive placebo. A sequential trial plan
using a two-sample sequential Wilcoxon test developed by
Skovlund and Walløe was used in the current study to keep
the number of women needed to reach a conclusion as low as
possible.31–33 This method has previously been used in clinical
trials and has been shown to be easy to use.34,35 It is expected
to reduce the number of women needed to reach a conclu-
sion compared with the number required in a corresponding
ﬁxed sample trial. We performed a small pilot study in our
department on 20 women prior to operative hysteroscopy in
January 2006 to investigate the preoperative variability (SD)
in cervical dilatation, in order to calculate the boundaries
needed for the statistical model. The SD was 1.3 mm in post-
menopausal women (n = 5) and 1.4 mm in premenopausal
women (n = 15). The mean cervical dilatation was 3.4 mm in
postmenopausal women and 5.4 mm in premenopausal
women. The chosen boundaries for the statistical model were
based on a signiﬁcance level of 5% and a power of 95% in
demonstrating a 1 mm difference in the cervical dilatation
caused by misoprostol and placebo (the primary end-point).
As it seemed unlikely that use of misoprostol could cause
a constriction of the cervix, a one-sided test was chosen.
When one of the boundaries was crossed, the trial was stop-
ped. In this case, crossing the lower boundary would have
meant that misoprostol was signiﬁcantly superior to placebo
and crossing the upper boundary would have meant that the
two treatments had been equally effective. Secondary end-
points were as follows: the number of women who achieve
satisfactory cervical priming (cervical dilatation ‡5 mm);
5 mm was chosen as ‘satisfactory’, as this would permit inser-
tion of a diagnostic hysteroscope without further dilatation. A
preoperative cervical dilatation of 5 mm would also make it
much easier to further dilate the cervix with Hegar dilators
if necessary (for insertion of an operative resectoscope of
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acceptability of self-administration of vaginal capsules at
home, the number of dilatations judged as ‘easy’ or ‘difficult’
by the operator, and the frequency of complications, as reg-
istered by the nurses preoperatively and the operators intra-
operatively. The trials were not designed nor powered to test
the difference for the secondary outcomes. Following the
sequential Wilcoxon test by Skovlund and Walløe, the esti-
mator of normal means is applied if the observations are
normally distributed.36
Approval from the Regional Committee for Medical
Research Ethics in Northern Norway37 was granted for the
study protocol on 23 May 2006. Permission from Ulleva ˚l
University Hospital’s Advisory Committee on the Protection
of Patient Records was granted on 31 May 2006 and from the
Norwegian Medicines Agency38 on 7 July 2006. The study
protocol was published on http://www.clinicaltrials.gov on
17 August 2006 and was submitted to the European Clinical
Trials Database during May 2006 and has previously been
published in BJOG.39 Each participating woman was insured
through the Drug Liability Association with liability insur-
ance in connection with clinical trials of drugs.
Results
The stopping boundaries were reached on 2 March (after 179
days) for the postmenopausal group (Figure 2), showing no
signiﬁcant difference between the placebo and misoprostol
groups on the primary outcome of preoperative cervical dila-
tation, and on 20 April 2007 (after 235 days) for the premen-
opausal group (Figure 3), showing a signiﬁcant difference
between the misoprostol and placebo groups on the primary
outcome. The two treatment groups were comparable regard-
ing basal clinical preoperative characteristics (Table 1). The
indications for operative hysteroscopy and the operative pro-
cedure in the two study groups are shown in Table 2. The
cervical dilations in the two treatment groups are shown in
Table 3. In the premenopausal women, the mean cervical
dilatation was 6.4 mm (SD 2.4) in the misoprostol group
and 4.8 mm (SD 2.0) in the placebo group, the mean differ-
ence in cervical dilatation being 1.6 mm (95% CI 0.5–2.7).
The cervical dilatations were normally distributed in the pre-
menopausal trial. In the postmenopausal women, the mean
cervical dilatation was 4.9 mm (SD 1.5) in the placebo group
and 3.4 mm (SD 2.7) in the misoprostol. The cervical dilata-
tions were not normally distributed in the postmenopausal
trial. The main adverse effect was lower abdominal pain
(Table 4), but 51% of the women who received misoprostol
experienced no pain, in contrast to 42% experiencing pain
characterised as mild or moderate—less or equal to menstrual
pain. Three women (7%) who received misoprostol reported
severe lower abdominal pain but did not take analgesics or
report on their symptoms prior to operation and study reg-
istration of complications.
Out of 67 premenopausal women, 46 (70%) found self-
administered vaginal capsules at home to be completely
acceptable, 9 (13%) fairly acceptable, 9 (13%) fairly unac-
ceptable and 3 (4%) completely unacceptable. Out of 21
postmenopausal women, 11 (52%) found self-administered
vaginal capsules at home to be completely acceptable, 5
(24%) fairly acceptable, 4 (19%) fairly unacceptable and 1
(5%) completely unacceptable. The main reason given for
unacceptability was the lack of vaginal applicators aiding
insertion.
There were a total of nine (11%) complications. Two seri-
ous complications occurred in women in the premenopausal
misoprostol group who underwent transcervical myoma
resections after the procedure was completed. One woman
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Figure 2. Continuation of the sequential test. The stopping boundaries and the sample path leading to the conclusion that misoprostol was not
signiﬁcantly different from placebo are shown. H0, boundary for the null hypothesis; HA, boundary for the alternative hypothesis.
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caesarean section) sustained a uterine perforation that was
not diagnosed during the operation. The woman was read-
mitted 4 days later with symptoms and signs of infection. A
curettage raised suspicion of a perforation in the uterine fun-
dus, which was then conﬁrmed by subsequent laparoscopy.
The other woman (who had previously had two vaginal deliv-
eries) started to bleed heavily from the uterine wall after the
myoma was removed during the operation. Haemostasis with
coagulation did not stop the bleeding, so a balloon catheter
was inserted and insufﬂated with 30 ml of saline for 12 hours.
The bleeding subsequently subsided. Her haemoglobin level
was 8.1 g/dl postoperatively, and she was offered and accepted
blood transfusion with two red blood cell units. These com-
plications were not judged to be misoprostol related. False
passages through the cervix during cervical dilatation
occurred in two women (one nulliparous and one with three
vaginal deliveries) in the premenopausal placebo group. A
false passage through the cervix and uterine perforation
occurred in one woman in the postmenopausal misoprostol
group, while a uterine perforation without further complica-
tions occurred in one woman in the postmenopausal placebo
group. Cervical lacerations during the procedure occurred in
one woman in the postmenopausal placebo group. Two
women in thepremenopausal placebo group wereambulatory
treated with antibiotics for postoperative endometritis and
a urinary tract infection, respectively. No further complica-
tions was reported.
Discussion
Our trials show that 1000 microgram misoprostol self-
administered vaginally by the woman 12 hours before oper-
ative hysteroscopy is safe and effective for cervical ripening
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Figure 3. Continuation of the sequential test. The stopping boundaries and the sample path leading to the conclusion that misoprostol was signiﬁcantly
superior to placebo are shown. H0, boundary for the null hypothesis; HA, boundary for the alternative hypothesis.
Table 1. Demographic characteristics of women in the two study groups according to dosage
Characteristic Premenopausal women Postmenopausal women
Self-administered
vaginal placebo
(n 5 35)
Self-administered
vaginal misoprostol
(n 5 34)
Self-administered
vaginal placebo
(n 5 11)
Self-administered
vaginal misoprostol
(n 5 12)
Age (years), mean (SD) 42.11 (5.4) 43.38 (6.8) 62.64 (6.0) 63.3 (6.3)
Body mass index (kg/m2), mean (SD) 25.2 (4.8) 24.1 (4.3) 28.8 (6.2) 24.6 (5.3)
Women currently using hormone therapy, n (%) 3 (8.8) 5 (14.7) 3 (27.3) 5 (41.7)
Total number of children born, mean (SD) 1.3 (1.4) 1.6 (1.3) 1.6 (0.8) 1.4 (1.2)
Number of vaginal deliveries, mean (SD) 1.1 (1.3) 1.2 (1.3) 1.3 (0.9) 1.3 (1.1)
Women delivered with caesarean sections, n (%) 4 (11.4) 10 (29.4) 2 (18.2) 1 (8.3)
Women with previous cervical dilatation, n (%) 19 (54.3) 10 (29.4) 4 (36.4) 4 (33.3)
Women with previous cone biopsy, n (%) 3 (8.8) 3 (8.8) 1 (9.1) 1 (8.3)
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menopausal women. Self-administered vaginal capsules at
home were considered highly acceptable; adverse effects were
few and comparatively minor. We acknowledge that severe
preoperative abdominal pain caused considerable anxiety and
discomfort to the three women concerned. The study infor-
mation form that each woman received prior to enrolment
contained information on known possible adverse effects,
including lower abdominal pain. However, we had not
informed the women that they could use off-prescription
analgesics if they experienced pain, and we revised our infor-
mation to all subsequent trial participants. No women in the
study used analgesics preoperatively.
The main strength of this study was that it was tailored to
reach a conclusion on the primary outcome as soon as the
difference was signiﬁcant, so that as few women as possible
were enrolled. A trial with a ﬁxed sample size with the same
primary end-point as ours would have required 151 premen-
opausal women (SD 2.4) and 151 postmenopausal women
(SD 2.4) analysed in order to obtain a power of 95% based
on a t test, assuming normally distributed observations and
equal variance in the two groups. For ethical reasons, it is
important to keep the number of women needed to reach
a conclusion in clinical trials as low as possible. Our sequen-
tial trial reached a conclusion, after including only 28% of
this patient number. In addition, premenopausal and
Table 2. Indications for operative hysteroscopy and operative procedure in the two study groups according to dosage
Premenopausal women Postmenopausal women
Self-administered
vaginal placebo
Self-administered
vaginal misoprostol
Self-administered
vaginal placebo
Self-administered
vaginal misoprostol
Referral reason (n 5 35), n (%) (n 5 34), n (%) (n 5 11), n (%) (n 5 12), n (%)
Abnormal uterine bleeding 26 (74) 31 (91) N/A N/A
Postmenopausal bleeding N/A N/A 6 (55) 8 (67)
Asymptomatic endometrial polyp 4 (11) 0 3 (27) 4 (33)
Infertility 5 (14) 2 (6) N/A N/A
Asymptomatic submucous myoma 0 1 (3) 1 (9) 0
Procedure (n 5 31), n (%) (n 5 34), n (%) (n 5 10), n (%) (n 5 11), n (%)
Transcervical polyp resection 10 (32) 8 (24) 7 (70.0) 10 (91)
Transcervical myoma resection 8 (26) 12 (35) 2 (20.0) 0
Transcervical endometrium resection 12 (39) 12 (35) 0 0
Resection of uterine septum 1 (3) 1 (3) N/A N/A
No treatment 0 1 (3) 1 (10.0) 1 (9)
N/A, not applicable.
Table 3. Intraoperative ﬁndings and distribution of cervical dilatation in the two treatment groups
Premenopausal women Postmenopausal women
Self-administered
vaginal placebo
(n 5 31)
Self-administered
vaginal misoprostol
(n 5 34)
Self-administered
vaginal placebo
(n 5 10)
Self-administered
vaginal misoprostol
(n 5 11)
Mean difference in cervical dilatation (mm) 1.6 (95% CI 0.5–2.7) N/A
Cervical dilatation (mm)
Mean (SD) 4.8 (2.0) 6.4 (2.4) 4.9 (1.5) 3.4 (2.7)
Median (range) 5 (,2t o8 ) 6( ,2t o1 1 ) 5( 3t o7 ) 4( ,2t o7 )
Number of women achieving cervical
dilatation ‚5 mm, n (%)
20 (65) 30 (88) 7 (70) 3 (27)
‘Difﬁcult dilatation’, n (%) 10 (32) 4 (12) 2 (20) 7 (64)
Dilatation time (seconds), mean (SD) 68 (59) 47 (24) 49 (29) 70 (48)
Exposure to capsules (minutes), mean (SD) 765 (92) 754 (101) 840 (103) 840 (118)
Frequency of complications 42 21
The misoprostol and operative hysteroscopy trial
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conclusion was not given as part of a subgroup analysis.
The study was designed and conducted strictly in adherence
with the CONSORT criteria,35 and the protocol was submit-
ted for peer review before the trial started including women.
Furthermore, the study included all consecutive women
referred to outpatient hysteroscopy and over 80% of women
referred were included and analysed, giving a population-
based study.
The main weakness was that six gynaecologists, not a single
operator, were involved in assessing the primary outcome.
Even though they were individually instructed in assessing
preoperative cervical dilatation, it is difﬁcult to be certain that
every doctor’s assessment was valid and reliable. The SD of
the primary outcome probably increased with the number of
operators. Furthermore, the sequential Wilcoxon test by
Skovlund and Walløe is optimised for full randomisation,
while we used block randomisation. These factors probably
resulted in the trial needing more participants to reach a con-
clusion, resulting in a later curtailment. Two women were
excluded from assessment and analysis after it was discovered
preoperatively that they had uterine synechias (Asherman’s
syndrome) after they had been included. Furthermore, one
woman was excluded from assessment and analysis because
her intrauterine myoma was too large to be removed by re-
sectoscopy. It was unfortunate that the women were not
excluded before recruitment as not being eligible for hystero-
scopy. However, the doctors recruiting the women at the
outpatient clinic were not the same as the operating gynae-
cologists at the hysteroscopy. It was the operating gynaecol-
ogist’s prerogative to decide whether the medical indication
warranted hysteroscopy and whether the women should be
analysed. However, the operators were blinded to which treat-
ment the women had received, and we have no reason to
suspect differential misclassiﬁcation. The operations were
planned independently of menstrual cycle and, consequently,
while the trial was underway, we discovered an effect modiﬁer
that we had not considered prior to study commencement:
some premenopausal women with bleeding disorders bled so
profusely before insertion of the capsules, that the active
ingredient most likely was ‘washed out’ of the vagina without
having any effect on cervical ripening. These women were
assessed on an intention-to-treat basis. Two of the three
women who spontaneously remarked that the tablets most
probably had been ‘washed out’ had a preoperative cervical
dilatation of 2 mm or less.
Our audit in 20063 supported previous studies that have
identiﬁed women at risk of complications from operative
hysteroscopy.2 GnRH agonist use, previous cone biopsy,
and markedly retroverted uterus are additional risk factors
for complications. It is not standard practice in Scandinavia
to pre-treat with GnRH analogues and none of the women in
our study had received them. In our current study, a substan-
tial number of premenopausal women in the placebo group
and postmenopausal women had a cervical dilatation that was
judged as ‘difﬁcult’ by experienced operators. We therefore
believe that pre-treatment with this regimen in premeno-
pausal women has the potential to facilitate dilatation,
shorten the operation, and lower the risk of complications.
Any randomised controlled trial designed to investigate com-
plications would need a very large sample size and would
probably be considered unethical. Misoprostol is a cheap drug
and the cost of pre-treating prior to hysteroscopy would be
negligible. Self-administration is easy and does not require
hospital resources, other than information.
Misoprostol had no effect on cervical dilatation in post-
menopausal women. A large number of the postmenopausal
women referred to our outpatient clinic during this study
were referred by their gynaecologists after failure to obtain
an endometrial sample due to cervical stenosis. We speculate
that whether the lack of estrogen is the main reason why
misoprostol does not have any signiﬁcant effect. We therefore
Table 4. Preoperative adverse effects in the two treatment groups and ﬁndings during treatment
Premenopausal women Postmenopausal women
Self-administered
vaginal placebo
(n 5 31)
Self-administered
vaginal misoprostol
(n 5 34)
Self-administered
vaginal placebo
(n 5 10)
Self-administered
vaginal misoprostol
(n 5 11)
Mean level of reported preoperative pain* (SD) 0.45 (1.2) 2.2 (2.5) 0.2 (0.6) 1.1 (2.8)
Occurrence of bleeding, n (%) 1 (3) 7 (21) 0 1 (8)
Shivering, n (%) 0 1 (3) 1 (10) 0
Diarrhoea, n (%) 0 1 (3) 0 0
Nausea, n (%) 1 (3) 0 0 1 (9)
Vaginal discharge, n (%) 1 (3) 0 0 0
*Measured with a visual analogue scale score, ranging from 0 (no pain) to 10 (unbearable pain).
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local hormone therapy combined with misoprostol might
have a positive cervical ripening effect on postmenopausal
women, are warranted.
Conclusions
One thousand micrograms of self-administered vaginal miso-
prostol administered 12 hoursprior to operative hysteroscopy
has a signiﬁcant cervical ripening effect compared with pla-
cebo in premenopausal but not in postmenopausal women.
We would recommend offering this inexpensive and easy to
use regimen to nulliparous premenopausal women prior to
undergoing operative hysteroscopy to reduce the risk of com-
plications and facilitate cervical dilatation. Self-administered
vaginal misoprostol of 1000 micrograms at home the evening
before operative hysteroscopy is safe and highly acceptable,
although a small proportion of women experienced severe
lower abdominal pain. There is a risk of lower abdominal
pain and light preoperative bleeding with this regimen and
women should be made aware of this and offered standard
analgesics.
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